Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR6002A + BR6002B
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
01
Overview
A fixed combination or co-administration of two investigational pharmaceutical agents, BR6002A and BR6002B, evaluated for pharmacokinetics and safety against single administration of BR6002 in healthy adults. The mechanism of action, active ingredients, and therapeutic targets are not disclosed in any available literature. Primary indications, molecular types, or pharmacological classes are currently unknown. The drug was investigated in a clinical trial to compare the pharmacokinetics and safety profile of BR6002 (single agent) versus the coadministration of its components, BR6002A and BR6002B, under fed or fasting conditions in healthy volunteers.
- Other names
- BR6002A + BR6002B
Beyond the preview
Go deeper on BR6002A + BR6002B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR6002A + BR6002B.